MarketScreener Homepage > Equities > Nasdaq > Alexion Pharmaceuticals, Inc. ALXN

Report

Delayed Nasdaq - 01/22 04:00:00 pm
159.73	USD		+1.18%

01/22

PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-

01/13

ALEXION PHARMACEUTICALS : pauses enrollment for COVID-19 study testing its rare blood-disorder drug

01/13

ALEXION PHARMACEUTICALS : Independent Panel Recommends Enrollment Cessation for Alexion Phase III Study of Ultomiris in Treatment of COVID-19

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

01/15/2021	01/19/2021	01/20/2021	01/21/2021	01/22/2021	Date
156.7(c)	158.71(c)	157.74(c)	157.86(c)	159.73(c)	Last
2 106 122	4 397 079	3 717 827	3 579 909	2 789 197	Volume
+0.03%	+1.28%	-0.61%	+0.08%	+1.18%	Change

More quotes

Financials (USD)

Sales 2020	5 980 M - -
Net income 2020	516 M - -
Net cash position 2020	808 M - -
P/E ratio 2020	68,7x
Yield 2020	-

Sales 2021	6 537 M - -
Net income 2021	2 430 M - -
Net cash position 2021	1 958 M - -
P/E ratio 2021	14,4x
Yield 2021	-

Capitalization	34 956 M 34 956 M -
EV / Sales 2020	5,71x
EV / Sales 2021	5,05x
Nbr of Employees	3 082
Free-Float	91,1%

More Financials

Company

Alexion Pharmaceuticals, Inc. specializes in the research and development of therapeutic products used in treating hematological and cardiovascular diseases, auto-immune diseases, and cancers. At the end of 2019, the group had a portfolio of 6 products in clinical development. Net sales are distributed geographically as follows: the United States (55.6%), Europe (24.2%), Asia/Pacific (10.6%) and other (9.6%).

Sector

Pharmaceuticals

Calendar

02/04

Ergebnisveröffentlichung

More about the company

Notations Surperformance© of Alexion Pharmaceuticals, Inc.

Trading Rating :

Investor Rating :

More Ratings

All news about ALEXION PHARMACEUTICALS, INC.

01/22	PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-	DJ
01/13	ALEXION PHARMACEUTICALS : pauses enrollment for COVID-19 study testing its rare ..	RE
01/13	ALEXION PHARMACEUTICALS : Independent Panel Recommends Enrollment Cessation for ..	MT
01/13	ALEXION PHARMACEUTICALS : pauses enrollment for COVID-19 study testing its rare ..	RE
01/13	ALEXION PHARMACEUTICALS : Provides Update on Phase 3 Study of ULTOMIRIS® (ravuli..	BU
01/12	ALEXION PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, R..	AQ
01/12	ALEXION PHARMACEUTICALS : Alexion Highlights Commercial, Clinical and Financial..	BU
01/08	ALEXION PHARMACEUTICALS : Raymond James Downgrades Alexion Pharmaceuticals to Ma..	MT
01/05	ALEXION PHARMACEUTICALS : to Present at the 39th Annual J.P. Morgan Healthcare C..	BU
01/05	ALEXION PHARMACEUTICALS : Stifel Adjusts Alexion Pharmaceuticals' Price Target t..	MT
2020	MARKET CHATTER : Dealmaking Worldwide Reportedly Falls to Three-Year Low in Year..	MT
2020	ALEXION PHARMACEUTICALS : Fewer companies caught the deal bug in the year of the..	RE
2020	Moderna Receives Price-Target Increase as Oppenheimer Sees COVID-19 Vaccine P..	MT
2020	SHAREHOLDER ALERT : Monteverde & Associates PC Announces an Investigation of Ale..	PR
2020	MODERNA, EXXON, ALPHABET, AMAZON : Stocks That Defined the Week	DJ

More news

News in other languages on ALEXION PHARMACEUTICALS, INC.

2020	MÄRKTE USA/Hoffnung auf Konjunkturpaket beflügelt Wall Street
2020	MÄRKTE USA/Hoffnung auf Konjunkturpaket hievt Wall Street ins Plus
2020	MÄRKTE USA/Hoffnungen auf Konjunkturpaket sorgen für Plus
2020	MÄRKTE USA/Hoffnungen auf Konjunkturpaket dürften für Plus sorgen
2020	WALL STREET STOCK EXCHANGE : S&P 500 cae en jornada de despliegue de vacuna y de..

More news

Analyst Recommendations on ALEXION PHARMACEUTICALS, INC.

01/08	ALEXION PHARMACEUTICALS : Raymond James Downgrades Alexion Pharmaceuticals to Ma..	MT
01/05	ALEXION PHARMACEUTICALS : Stifel Adjusts Alexion Pharmaceuticals' Price Target t..	MT
2020	ALEXION PHARMACEUTICALS : Truist Securities Downgrades Alexion Pharmaceuticals t..	MT

More recommendations

Provided by Scoopnest.com

Analysis

Alexion Pharmaceuticals : Fewer companies caught the deal bug in the year of the pandemic

More Must read

Chart ALEXION PHARMACEUTICALS, INC.

Duration : Period :

Alexion Pharmaceuticals, Inc. Technical Analysis Chart | ALXN | US0153511094 | MarketScreener

Full-screen chart

Technical analysis trends ALEXION PHARMACEUTICALS, INC.

	Short Term	Mid-Term	Long Term
Trends	Bullish	Bullish	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	HOLD
Number of Analysts	19
Average target price	177,00 $
Last Close Price	159,73 $
Spread / Highest target	25,2%
Spread / Average Target	10,8%
Spread / Lowest Target	3,30%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Ludwig N. Hantson	Chief Executive Officer & Director
Aradhana Sarin	President & Director
David Richard Brennan	Chairman
Brian M. Goff	Chief Commercial, Global Operations Officer & EVP
John J. Orloff	Executive VP, Head-Research & Development

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

ALEXION PHARMACEUTICALS, INC.	1.04%	34 956



CSL LIMITED	-3.03%	96 409
SAMSUNG BIOLOGICS CO.,LTD.	-3.87%	47 496
BIOGEN INC.	10.04%	41 462
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.	10.88%	40 484
UCB	3.67%	20 143

More Results